Tivozanib: a novel VGFR inhibitor for kidney cancer

Treatment of kidney cancer has changed over the past 10 years with the approval of several targeted agents. These drugs are given on a long term base and toxicity is an issue for most patients. Despite improvement compared to immunotherapy, most patients will progress on these drugs. There is a need...

Descripción completa

Detalles Bibliográficos
Autor principal: Boyle, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2013
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708224/
https://www.ncbi.nlm.nih.gov/pubmed/26816733
http://dx.doi.org/10.3978/j.issn.2223-4683.2012.07.04
Descripción
Sumario:Treatment of kidney cancer has changed over the past 10 years with the approval of several targeted agents. These drugs are given on a long term base and toxicity is an issue for most patients. Despite improvement compared to immunotherapy, most patients will progress on these drugs. There is a need for more portent and better tolerated drugs. Tivozanib is a potent pan VEGR specific inhibitor. In this phase II trial it gave interesting results with an overall median PFS throughout the study of 11.7 months (95% CI: 8.3-14.3 months) and an overall objective response rate of 24% (95% CI: 19-30%). “Off”-target toxicity was mild.

Ejemplares similares